We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Immunotherapy for skin cancer.
- Authors
Paulson, Kelly G; Lahman, Miranda C; Chapuis, Aude G; Brownell, Isaac
- Abstract
Among all tumor types, skin cancers are profoundly sensitive to immunotherapy. Indeed, the recently reported response rates for anti-PD-1 (anti-programmed-death 1) therapy for cutaneous malignant melanomas (MM), Merkel cell carcinomas, basal cell carcinomas, cutaneous squamous cell carcinomas and Kaposi sarcomas are all above 40%. This unique immunogenicity renders skin cancers as a paradigm for tumor–immune interactions and is driven by high mutational burdens, over-expressed tumor antigens and/or viral antigens. However, despite the clear demonstration of immunologic cure of skin cancer in some patients, most tumors develop either early (primary) or late (adaptive) resistance to immunotherapy. Resistance mechanisms are complex, and include contributions of tumor cell-intrinsic, T cell and microenvironment factors that have been recently further elucidated with the advent of single-cell technologies. This review will focus on the exciting progress with immunotherapy for skin cancers to date, and also our current understanding of the mechanisms of resistance to immunotherapy.
- Subjects
SKIN cancer; IMMUNOTHERAPY
- Publication
International Immunology, 2019, Vol 31, Issue 7, p465
- ISSN
0953-8178
- Publication type
Article
- DOI
10.1093/intimm/dxz012